



australasian society of clinical immunology and allergy

23 May 2023

Professor Andrew Wilson
Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
MDP 952, GPO Box 9848
Canberra, ACT 2601
Email: pbac@health.gov.au

Dear Professor Wilson,

Re: Tavneos® (Avacopan) application for Severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA)

This submission is made on behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.

We write in support of the following application which is on the July 2023 meeting agenda for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC), for Pharmaceutical Benefits Scheme (PBS) listing.

AVACOPAN

Tavneos® - Vifor Pharma Pty Limited

Capsule 10 mg

Clinical indication: Severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA)

Proposed new PBS listing: To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of severe active GPA and severe active MPA in combination with rituximab or cyclophosphamide/azathioprine.

ASCIA supports this application for PBS listing for the following reasons:

- Clinical immunology/allergy specialists manage patients with vasculitis disorders including GPA and MPA, but current treatments have limitations, including effectiveness in controlling disease and side effects.
- There are considerable costs to patients and the healthcare system due to delayed or inadequate treatment of severe GPA and MPA, associated with medical consultations for poorly controlled disease.
- The new PBS listing of Tavneos® should improve access to effective therapeutic options for patients with severe GPA and MPA, which can be lifelong and impact quality of life.

We hope that the PBAC will take into account the reasons listed above, in support of the application for PBS listing of Tavneos®.

Please do not hesitate to contact us by emailing jill@allergy.org.au for further information.

Yours sincerely,

A/Professor Theresa Cole
ASCIA President

Jill Smith
ASCIA CEO